newsadvanced cancerAntibody-drug conjugate
Farletuzumab Ecteribulin: Optimizing Dosing to Mitigate Lung Toxicity While Targeting Folate Receptor Alpha in Advanced Cancers
By MedXY|Oct 10, 2026
This phase 1/2 study evaluates farletuzumab ecteribulin, a folate receptor alpha-targeting ADC, showing that fractionated dosing reduces interstitial lung disease risk and demonstrates preliminary antitumor activity in advanced ovarian, end